|Table of Contents|

Correlation of serum TNF-α，IL-6 and VEGF of patients with differentiated thyroid carcinoma and its invasion and metastasis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2015 06
Page:
771-774
Research Field:
Publishing date:

Info

Title:
Correlation of serum TNF-α，IL-6 and VEGF of patients with differentiated thyroid carcinoma and its invasion and metastasis
Author(s):
Hu Jinhua; Zhang Yaoqing; Ai Ruihua; Zhu Bin
The Second Department of General Surgery,Jingshan People's Hospital of Hubei Province,Hubei Jingmen 431899,China.
Keywords:
thyroid carcinoma; TNF-α; IL-6; VEGF; tumor staging; lymphatic metastasis
PACS:
R736.2
DOI:
10.3969/j.issn.1672-4992.2015.06.13
Abstract:
Objective:To explore the correlation of serum TNF-α,IL-6，VEGF of patients with differentiated thyroid carcinoma and its invasion and metastasis.Methods:Serum levels of TNF-α,IL-6 and VEGF were detected by ELISA in 64 cases of differentiated thyroid carcinoma(thyroid carcinoma group) and 42 cases of thyroid adenoma(thyroid adenoma group),and 40 healthy people as control group.Results:The serum concentrations of TNF-α,IL-6 and VEGF in thyroid cancer group were higher than that in thyroid adenoma group and control group(P＜0.01).Among thyroid carcinoma cases,the levels of the three markers in stage Ⅳ>stage Ⅲ> stage Ⅰ and Ⅱ(P＜0.01),and that in patients with cervical lymphatic metastasis > without metastasis(P＜0.01).There were no significant differences between different gender groups and among different age groups(P＞0.05).Conclusion:The serum levels of TNF-α,IL-6 and VEGF are closely related to the invasion and metastasis of differentiated thyroid carcinoma.There is of great significance of TNF-α,IL-6 and VEGF serum levels for judging the severity of patients with differentiated thyroid carcinoma.

References:

[1]陈祯勇.分化型甲状腺癌外科治疗的研究进展［J］.当代医学，2013，19（2）：12-13.
[2]庄晓明.肿瘤坏死因子-α、白细胞介素-6和白细胞介素-2受体与甲状腺肿瘤的相关性研究［J］.中华实用诊断与治疗杂志，2010，24（1）:32-36.
[3]Zhou ZH,Cui XN,Xing HG,et al.Changes and prognostic value of serum vascular endothelial growth factor in patients with differentiated thyroid cancer［J］.Med Princ Pract,2013,22(1):24-28.
[4]常旭，赵树鹏.肿瘤微环境通过功能性干细胞因子增强肥大细胞促甲状腺癌生长潜能［J］.广东医学，2012，33（12）：1715-1717.
[5]Garcia-Roman J,Zentella-Dehesa A.Vascular permeability changes involved in tumor metastasis［J］.Cancer Lett,2013,335(2):259-269.
[6]石秀敏,刘伟,高素君.炎症标志物与肺癌关系的研究进展［J］.现代肿瘤医学，2010，18（12）：2501-2505.
[7]Korobowicz A.Biology of tumor necrosis factor type alpha(TNF-alpha)［J］.Pol Merkur Lekarski 2006,21(124):358-361.
[8]Zidi I,Mestiri S,Bartegi A,et al.TNF-alpha and its inhibitors in cancer ［J］.Med Oncol,2010,27(2):185-198.
[9]侯健，王东.人类细胞因子手册［M］.上海:同济大学出版社，1995：1543-1551.
[10]殷咏梅，束永前，陈晓锋，等.TNF-α通过JNK和AP-1途径调节乳腺癌MCF-7细胞VEGF的表达［J］.中国肿瘤生物治疗杂志，2009，16（1）：12－17.
[11]汪永旭，蒋伟丰，朱陈宏.STAT3和VEGF-C在甲状腺癌中表达及其与临床病理特征关系［J］.肿瘤学杂志，2013，19（2）：118-121.
[12]王景霞，徐辉，邓文伟，等.VEGF-C和TNF-α在乳头状与滤泡状甲状腺癌肿的表达及其意义［J］.中国老年学杂志，2009，29（13）：1617-1618.
[13]伍石华.甲状腺肿瘤组织中VEGF及其受体表达与临床病理的联系［J］.临床肿瘤学杂志,2006,11(5):371-372.
[14]田亮,赵瑾.甲状腺癌淋巴管生成与转移的研究进展［J］.现代肿瘤医学，2010，18（2）：413-415.
[15]刘徽，朱波，林治华.IL-6信号通路与肿瘤［J］.细胞与分子免疫学杂志，2011，27（3）：353－355.
[16]Lippitz BE.Cytokine patterns in patients with cancer:A systematic review［J］.Lancet Oncol,2013,14(6):218-228.
[17]Iliopoulos D，Hirsch HA，Struhl K．An epigenetic switch involving NF-kappaB，Lin28，Let-7 microRNA，and IL-6 links inflammation to cell transformation［J］． Cell，2009，139(4):693-706．

Memo

Memo:
荆门市科学技术局科研项目(编号:2012YD40)
Last Update: 2015-02-02